In PC cell lines, olaparib significantly increased tumor cell sensitivity to NK-mediated killing and antibody-dependent cytotoxicity (ADCC), regardless of BRCA status, PD-L1, or epithelial growth factor receptor (EGFR) modulation [129]. The gene discussed is EGFR; the disease is neoplasm.